RCMU
IMCR icon

Rokos Capital Management (UK)’s Immunocore IMCR Stock Holding History

Rokos Capital Management (UK)’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$21K – 147
2021
Q1 		$21K Buy
+500
New +$22.3K ﹤0.01% 112

Other funds holding IMCR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BCPEMI
Bain Capital Public Equity Management II Boston, Massachusetts $62.1M AUM 25.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Rokos Capital Management (UK)'s IMCR Position: Q2 2021 in Review

Rokos Capital Management (UK) sold out of Immunocore (IMCR) in Q2 2021, closing a stake of 500 shares — an estimated $21K sold.

Rokos Capital Management (UK) first reported a position in IMCR in Q1 2021 and held it in 1 quarter. The position peaked at $21K in Q1 2021. 45 funds tracked by Wall St. Rank hold IMCR as of Q2 2021.

  • Rokos Capital Management (UK) reported no remaining Immunocore position as of Q2 2021 after selling out during the quarter.
  • Rokos Capital Management (UK) sold 500 Immunocore shares in Q2 2021, an estimated $21K.
  • Rokos Capital Management (UK) first reported a position in Immunocore in Q1 2021 and held it in 1 quarter.
  • Rokos Capital Management (UK)'s Immunocore position peaked at $21K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Immunocore as of Q2 2021.

Based on Rokos Capital Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.